Ausra Deluard joined Dentons in 2019. She is a partner and co-chair of the US Competition and Antitrust group. She advises clients across a broad range of sectors on contentious and non-contentious antitrust matters relating to proposed mergers and acquisitions, gun-jumping, global pricing and distribution policies, competitor collaborations and licensing arrangements. Ausra Deluard also has notable experience advising healthcare clients, including large health systems, provider groups and insurers, which has deepened her understanding of the sector’s market dynamics and challenges, including those that arise in transaction planning and competitor collaborations. She also advises clients in the nascent cannabis industry on rapidly evolving laws and regulations. She teaches antitrust mergers as an adjunct professor at U.C. Hastings School of Law and is active in the International and Antitrust Sections of the American Bar Association and has written extensively on antitrust-related issues. She also has worked on programs engaging underprivileged inner city youth in sailing.
47
Last week the U.S. Congress plugged a significant gap in existing federal whistleblower protection laws by passing the Criminal Antitrust Retaliation Act, which prohibits employers from retaliating against employees, contractors and agents that report potential violations of federal antitrust (...)
325
To resolve charges that its $2.1 billion acquisition of Liberty Dialysis Holdings, Inc. (Liberty) would harm competition in 43 local markets throughout the United States, Fresenius Medical Care AG & Co. KGaA (Fresenius) agreed to divest 60 outpatient dialysis clinics. U.S.-based (...)
504
Healthcare reform and concerns about consolidation in the health care industry juxtaposed with continuing economic distress provided a fascinating backdrop for the Federal Trade Commission’s (FTC’s) recent investigation of Scott & White Healthcare’s consummated acquisition of King’s (...)
